Living with
Lilly’s Omvoh shows improved outcomes in ulcerative colitis
The phase 3 trial results demonstrated improved symptomatic, clinical and quality-of-life measures
J&J’s Tremfya approved by MHRA to treat Crohn’s disease and ulcerative colitis
Inflammatory bowel disease is estimated to affect more than 500,000 people in the UK
Johnson & Johnson shares long-term results for Tremfya in ulcerative colitis
More than 2.5 million people in Europe are affected by the inflammatory bowel disease
Johnson & Johnson’s Tremfya granted EC approval to treat ulcerative colitis in adults
More than 2.5 million people in Europe are living with the inflammatory bowel disease
J&J receives three CHMP recommendations for immunology and oncology indications
Tremfya, Stelara and Darzalex have been recommended for ulcerative colitis, Crohn’s disease and multiple myeloma, respectively
J&J’s shares positive results for subcutaneous Tremfya in phase 3 ulcerative colitis trial
Inflammatory bowel disease affects almost one in every 100 people in the US
ICR researchers uncover new method for predicting bowel cancer risk in IBD patients
Approximately 500,000 people in the UK are affected by Crohn’s disease or ulcerative colitis
Johnson & Johnson’s IL-23 inhibitor Tremfya granted FDA approval for ulcerative colitis
The inflammatory bowel disease is estimated to affect more than one million people in the US
AbbVie’s IL-23 inhibitor Skyrizi approved by EC to treat ulcerative colitis in adults
The form of inflammatory bowel disease is estimated to affect five million people globally
AbbVie’s IL-23 inhibitor Skyrizi approved by FDA to treat ulcerative colitis in adults
The inflammatory bowel disease affects more than one million people in the US
Infographic: Therapy Watch Acute Myeloid Leukemia market snapshot
This Acute Myeloid Leukemia infographic offers a snapshot of the real-world patient insights collected by our Therapy Watch study, based on data collected from a panel of 220 physicians across...
How we provided comprehensive real-world patient data for PAH using Therapy Watch, our syndicated market tracking solution
PAH is a specific type of pulmonary hypertension, which is a rare condition treated primarily in specialized centers. Our client needed to gain a comprehensive understanding of PAH patients, such...